Synjardy (empagliflozin/metformin) / Eli Lilly, Boehringer Ingelheim  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Synjardy (empagliflozin/metformin) / Boehringer Ingelheim, Eli Lilly
TERA 305, NCT05504226: Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin 25 mg and Metformin

Recruiting
3
208
RoW
Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet, Teneligliptin Placebo Oral Tablet
Handok Inc.
Type 2 Diabetes
11/24
05/25
TERA 304, NCT05504239: Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin

Recruiting
3
228
RoW
Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet, Teneligliptin Placebo Oral Tablet
Handok Inc.
Type 2 Diabetes
11/24
03/25
NN9924-7663, NCT06083675: Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

Withdrawn
3
912
Europe, US, RoW
Semaglutide, Empagliflozin, Metformin
Novo Nordisk A/S
Diabetes Mellitus, Type 2
01/25
05/27

Download Options